Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Characteristics of MIT-001 After Subcutaneous and Intravenous Administration in Healthy Subjects

NCT05389696 is registered in ClinicalTrials.gov with MitoImmune Therapeutics as lead sponsor.

NCT NCT05389696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05389696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Characteristics of MIT-001 After Subcutaneous and Intravenous Administration in Healthy Subjects
Lead sponsor
MitoImmune Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 13, 2022
Completion date
April 28, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heathly subjects